Measuring quality of life: impact of chemotherapy for advanced colorectal cancer. Experience from two recent large phase III trials
1998

Impact of Chemotherapy on Quality of Life in Advanced Colorectal Cancer

Sample size: 247 publication Evidence: moderate

Author Information

Author(s): H Anderson, MK Palmer

Primary Institution: Christie and Wythenshawe Hospitals, Manchester, UK

Hypothesis

Raltitrexed would have similar efficacy but fewer side-effects than 5-FU, leading to improved quality of life.

Conclusion

Raltitrexed showed early advantages in quality of life compared to 5-FU plus LV, but the overall quality of life results were not significantly different.

Supporting Evidence

  • Patients receiving raltitrexed had statistically significant advantages in quality of life at week 2 in several dimensions.
  • Raltitrexed caused less grade 3 or 4 toxicity compared to 5-FU plus LV.
  • Overall survival was significantly longer in the chemotherapy group than in the best supportive care group.

Takeaway

This study looked at how two cancer treatments affect patients' quality of life, finding that one treatment might be better at first but both have their pros and cons.

Methodology

Patients with advanced colorectal cancer were treated in two multicentre, international phase III trials comparing raltitrexed with 5-FU plus leucovorin, assessing quality of life using validated questionnaires.

Potential Biases

Potential biases due to missing data and differences in treatment schedules.

Limitations

The quality-of-life questionnaires were not administered frequently enough to detect early differences in toxicity.

Participant Demographics

Patients with advanced colorectal cancer, with a mix of performance status scores.

Statistical Information

P-Value

P = 0.0041

Confidence Interval

95% CI 1.29-3.77

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication